|
|
5-day change | 1st Jan Change | ||
|
20.30 USD |
-23.22% | -26.99% | -27.25% | |
Published on 06/12/2025 at 15:26
© MT Newswires – 2025
|
Sector Update: Tech |
03:26pm |
MT |
|
Top Midday Decliners |
02:26pm |
MT |
|
Sector Update: Health Care Stocks Lean Lower Premarket Thursday |
09:21am |
MT |
|
Simulations Plus Cuts Full-Year Revenue Outlook; Shares Down Pre-Bell |
05:23am |
MT |
|
Simulations Plus Reports Preliminary Fiscal Q3 Revenue; Lowers Fiscal 2025 Revenue Outlook; Shares Fall After Hours |
Jun. 11 |
MT |
|
Simulations Plus, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of Fiscal 2025 |
Jun. 11 |
CI |
|
Simulations Plus, Inc. Releases ADMET Predictor 13 |
Jun. 05 |
CI |
|
Simulations Plus To Reduce Workforce By 10% – SEC Filing |
Jun. 02 |
RE |
|
Simulations Plus, Inc. Announces Management Changes, Effective May 30, 2025 |
Jun. 02 |
CI |
|
Simulations Plus, Inc. Releases DILIsym 11 |
May. 15 |
CI |
|
Simulations Plus Insider Sold Shares Worth $670,150, According to a Recent SEC Filing |
May. 01 |
MT |
|
Simulations Plus, Inc. Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies |
Apr. 21 |
CI |
|
Simulations Plus, Inc., Q2 2025 Earnings Call, Apr 03, 2025 |
Apr. 03 |
|
|
Simulations Plus Q2 Earnings Lower, Sales Higher; Sets Outlook |
Apr. 03 |
MT |
|
Simulations Plus, Inc. Provides Earnings Guidance for the Year 2025 |
Apr. 03 |
CI |
|
Simulations Plus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2025 |
Apr. 03 |
CI |
|
Simulations Plus Insider Sold Shares Worth $573,600, According to a Recent SEC Filing |
Mar. 04 |
MT |
|
Simulations Plus Insider Sold Shares Worth $678,243, According to a Recent SEC Filing |
Feb. 04 |
MT |
|
Simulations Plus Partners With Enabling Technologies Consortium to Advance GastroPlus Platform |
Jan. 22 |
MT |
|
Simulations Plus, Inc. and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus®? Enhancements |
Jan. 22 |
CI |
|
World Bank warns that US tariffs could reduce global growth outlook |
Jan. 16 |
RE |
|
KeyBanc Lowers Price Target on Simulations Plus to $35 From $40, Keeps Overweight Rating |
Jan. 08 |
MT |
|
Tranche Update on Simulations Plus, Inc.’s Equity Buyback Plan announced on January 4, 2023. |
Jan. 08 |
CI |
|
Simulations Plus, Inc., Q1 2025 Earnings Call, Jan 07, 2025 |
Jan. 07 |
|
|
Simulations Plus Fiscal Q1 Adjusted EPS Down, Revenue Up; Guidance Unchanged — Shares Drop After Hours |
Jan. 07 |
MT |
SLP: Dynamic Chart
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
More about the company
Buy
Average target price
36.25USD
Spread / Average Target
+37.10%
Consensus
Select your edition
All financial news and data tailored to specific country editions
